ALGS240920C2500
- 0.03
- 0.000.00%
Aligos Therapeutics Newsroom
H.C. Wainwright Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $75
Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)
Aligos Therapeutics Analyst Ratings
Aligos Therapeutics (ALGS) Receives a Buy From Piper Sandler
Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
Maintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics' Clinical Pipeline
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Aligos Therapeutics (ALGS)
Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
Analysts Offer Insights on Healthcare Companies: Agilent (A), Cytokinetics (CYTK) and Aligos Therapeutics (ALGS)
Aligos Therapeutics (ALGS) Gets a Buy From Piper Sandler
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), Aligos Therapeutics (ALGS) and Nektar Therapeutics (NKTR)
Piper Sandler Sticks to Its Buy Rating for Aligos Therapeutics (ALGS)
Aligos Therapeutics (ALGS) Receives a Buy From Piper Sandler
SVB Securities Remains a Hold on Aligos Therapeutics (ALGS)
SVB Securities Sticks to Its Hold Rating for Aligos Therapeutics (ALGS)
Piper Sandler Sticks to Its Buy Rating for Aligos Therapeutics (ALGS)
Aligos Therapeutics Analyst Ratings
Piper Sandler Maintains Overweight on Aligos Therapeutics, Raises Price Target to $7
SVB Securities Sticks to Its Hold Rating for Aligos Therapeutics (ALGS)